Vivalis, Sanofi Pasteur in infectious mAb deal

Vivalis S.A. (Euronext:VLS) granted Sanofi Pasteur, the vaccines division of sanofi-aventis Group (Euronext:SAN; NYSE:SNY), exclusive access to its Humalex platform to discover human mAbs against nosocomial and other non-vaccine-preventable infections. Sanofi Pasteur will fund research of the mAbs and have exclusive, worldwide rights to develop and commercialize resulting drug candidates. Vivalis will receive EUR 3 million ($3.6 million) up front. Vivalis is also eligible for up to EUR 35 million ($41.8 million) in milestones for each indication, plus royalties. ...